Biotechnology / Medical Research
Techne Corp Announces Acquisition Agreement
Techne Corp announced that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Bionostics is engaged in the development, manufacture and distribution of control solutions that verify the proper operation of in vitro...
iCo Therapeutics Inc Updates On iDEAL Phase 2 Study For Treatment Of Diabetic Macular Edema
iCo Therapeutics Inc announced that the iDEAL trial explores whether varying combinations and concentrations of iCo-007 are effective in improving visual acuity in people with DME-the cause of functional visual loss among working Americans, in which leakage of fluid from blood vessels in the eye...
Silence Therapeutics Plc Updates On Progressing Phase Ib/IIa Study
Silence Therapeutics Plc announced that the Data Safety Monitoring Board (DSMB) has unanimously recommended the continuation of the Phase Ib/IIa study of Atu027. The Phase Ib/IIa study uses Atu027 in combination with gemcitabine, a chemotherapy agent in patients with advanced pancreatic cancer...
Elan Corporation PLC Advises Shareholders To Withdraw Any Acceptances Of Royalty Pharma Offer And Not To Tender Any Further Acceptances Into This Lapsed Offer
Elan Corporation PLC announced that Elan Shareholders to withdraw any acceptances of Royalty Pharma’s Offer without delay and not to tender any further acceptances. Following the outcome of the Elan EGM June 17,2013 morning, and in accordance with the terms of the Royalty Pharma Offer, the Royalty...
Mergers & Acquisitions
- Techne Corp Announces Acquisition Agreement
- Elan Corporation PLC Advises Shareholders To Withdraw Any Acceptances Of Royalty Pharma Offer And Not To Tender Any Further Acceptances Into This Lapsed Offer
- Imprimis Pharmaceuticals Inc Announces Completion Acquisition Of Intellectual Property Assets From Buderer Drug Company
Markets
- Sectors
- U.S.
- Europe
- Asia
Sector Summary
| Energy |  +0.48% |
| Basic Materials |  -0.12% |
| Industrials | +0.57% |
| Cyclical Goods & Services | +0.61% |
| Non-Cyclical Goods & Services | +0.09% |
| Financials | +0.60% |
| Healthcare | +0.35% |
| Technology | +0.65% |
| Telecoms | +0.59% |
| Utilities | +0.66% |
| DOW | 15,318.23 | +138.38 |
+0.91% |
| S&P 500 | 1,651.81 | +12.77 |
+0.78% |
| NASDAQ | 3,482.18 | +30.05 |
+0.87% |
| TR US Index | 149.80 | +1.16 |
+0.78% |
Upcoming Events
No related earnings announcements are currently scheduled within the next 7 days.
Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
